Urvashi Prasad is a public policy specialist at NITI Aayog, the Indian Government’s premier think tank. She is also the founder of Every Voice, a platform that highlights the perspectives, needs, challenges and aspirations of people living in poverty in their own words. Urvashi was previously a Director at Operation ASHA, one of India’s largest tuberculosis control NGOs. She also led the health portfolio of the Michael & Susan Dell Foundation in India for five years. Urvashi is on the governing board of Partnership for TB Care & Control, the largest tuberculosis network in India. She completed her Bachelors in Genetics from University of Birmingham, UK, followed by a Masters in Bioscience Enterprise from University of Cambridge, UK and a Masters in Public Health from the London School of Hygiene & Tropical Medicine. Urvashi is passionate about gender-related and animal welfare issues. She is also a blogger and writes extensively for several platforms including the Huffington Post and Nextbillion.net.
Dr Maruthi Viswanathan is the Founder and Chief Executive Officer of a digital startup RxPrism Health Systems located in the Silicon Valley of India. A physician by education, Dr Maruthi is a dynamic visionary with international expertise in scientific education, medico-marketing communication, medical simulations, mobile applications, and innovative healthcare systems for patients and healthcare providers alike. Dr Maruthi has developed a unique 3-D software for scientific visualization and has several copyrights to his credit. An innovator par excellence, he has ideated, designed, and deployed a multitude of digital options for the top pharmaceutical companies worldwide.
Including, how data transparency in clinical trials can transform patient recruitment and engagement.
Hitesh Thakrar is a Partner of Syncona Investment Management Ltd. He is an experienced investor in the sector, having spent over 20 years investing in public global equities in the life sciences, technology and the innovation sectors.
He has worked at various institutions in equity research and Fund Management from ADIA, the sovereign wealth Fund of Abu Dhabi, JP Morgan, Aviva Group, Dresdner Bank and New Star Asset Management. He has a strong track record, rated AA manager and was also a top 1 percentile manager in global equities. He is on the Board of Desktop Genetics, a CRISPR IP library company, backed by Illumina and is an angel investor in early stage Innovation companies. He is also on the Investment Committee of the LBA Scale Up Innovation Fund.
Hitesh holds a degree in Chemistry from Kings College, London, MBA from Cranfield University and CFA, the American Association of Investment Analysts.
AI, mHealth, IoT, big data, social media; there's no doubt that technology is changing clinical trials. However, everyone has different ideas about how best to use these technologies and where they are taking the trials of the future. Additionally, with innovative trial designs, increasingly patient-centric approaches, biomarkers and personalised medicine, clinical trials could look very different in 5, 10 or 20 years.